Payers are watching whether FDA's evolving policy on designating insulins as biologics may inhibit competition from less expensive products and worry that innovator products could gain extended marketing exclusivity as part of the transition.
The government "is considering re-categorizing insulins as biologics, which could extend patent protection in a category that already is experiencing...